51²è¹Ý¶ù

Our ARVs

IPM works with cutting-edge ARV compounds as a result of our partnerships with pharmaceutical companies. Through royalty-free licensing agreements for eight ARVs or active pharmaceutical ingredients and exclusive worldwide rights for one ARV called dapivirine,Ìýwe have access to an array of drugs with a variety of mechanisms of action against HIV infection.

The table below provides information on howÌýIPM compounds work and their stage of development at IPM. Our page lists IPM clinical trials that are currently under way.

IPM-licensed ARVs

CompoundLicenseMechanism of actionIPM development stage
Janssen Sciences Ireland Unlimited Company (previously Tibotec)NNRTI: Reverse transcription
  • Regulatory: EMA positive opinion received; country submissons planned
  • Clinical: Phase IIIb - completedÌý (dapivirine ring)
  • Phase II- completedÌýÌýÌý (dapivirine gel)
  • Phase I- ongoing (dapivirine-contraceptive ring)
  • Phase I-ongoing*Ìý Ìý(dapivirine rectal gel)
  • Phase I- completed (dapivirine-darunavir gel; dapivirine film)
(BMS793)BMSgp120: Cell attachment
  • Clinical: Phase I -ÌýcompletedÌý(DS003 vaginal tablet)
  • ±Ê°ù±ð³¦±ô¾±²Ô¾±³¦²¹±ôÌý(¶Ù³§003-»å²¹±è¾±±¹¾±°ù¾±²Ô±ðÌý°ù¾±²Ô²µ)
Janssen Sciences IrelandÌýUnlimited CompanyÌýProtease inhibitor: Protein synthesis and assembly
  • PreclinicalÌý(darunavir-based combination ring)
ViiV HealthcareCCR5: Cell Attachment
  • Clinical: Phase I-ÌýcompletedÌý(maraviroc vaginal and rectal gels)
  • Phase I- completed (maraviroc ring; dapivirine-maraviroc ring)
TenofovirGileadNRTI: Reverse transcriptionÌý
  • Preclinical**
DS001 (L167), DS004 (L872), DS005 (L882)MerckCCR5: Cell Attachment
  • Early preclinical
DS007 (L-644 peptide)Merckgp41: Cell fusion
  • Early preclinical

*ÌýTrial product provided by IPM
** Compound is in different stages of development by other organizations

Ìý

IPM’s active compounds target different steps in viral replication

The candidate microbicides in IPM’s product pipeline target four different steps in the viral replication cycle: attachment, fusion, reverse transcription, and protein synthesis and assembly.

  • Cell attachment: Preventing the virus from attaching to human cells
  • Cell fusion: Preventing the virus from entering human cells
  • Reverse transcription: Preventing the virus from reproducing inside human cells
  • Protein synthesis and assembly: Preventing the virus from producing new virus that can infect healthy cells

Learn more about .